Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lorcaserin hydrochloride Clear all
Completed Phase 4 Interventional Results available

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

NCT01987427
View directory record Official record
Conditions
Chronic Weight Management
Interventions
lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Not listed Phase 2 Interventional

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT03812523
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
Duloxetine 60 mg qd, Lorcaserin
Drug
Lead sponsor
Southeastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

NCT00395135
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg BID, Matching Placebo BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

NCT02044874
View directory record Official record
Conditions
Smoking Cessation
Interventions
APD356-lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
31
States / cities
Encino, California • Escondido, California • Los Alamitos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

NCT03338296
View directory record Official record
Conditions
Obesity
Interventions
lorcaserin hydrochloride XR, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • Bell Gardens, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

NCT02398669
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

NCT02022956
View directory record Official record
Conditions
Pharmacokinetics in Obese Adolescents
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

NCT00603902
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Lorcaserin, Cocaine Intravenous (IV), Placebo comparator
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 23, 2026, 4:32 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

NCT02400359
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Lorcaserin HCl, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin in the Treatment of Cocaine Use Disorder

NCT03007394
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Lorcaserin, Placebo Oral Capsule
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake

NCT00829140
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Lorcaserin 10mg BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 23, 2026, 4:32 AM EDT